GlaxoSmithKline, Medicago to Develop Novel Adjuvanted Covid-19 Candidate Vaccine
July 07 2020 - 9:10AM
Dow Jones News
By Ian Walker
GlaxoSmithKline PLC said Tuesday that it has formed a
collaboration with Canadian biopharmaceutical company Medicago to
develop a novel adjuvanted Covid-19 candidate vaccine.
The pharmaceutical giant said that phase 1 clinical testing will
start in the middle of July and that the companies hope to have the
vaccine ready for the first half of 2021. The companies also plan
to use their technologies to develop vaccines for other infectious
diseases.
The vaccine combines Medicago's recombinant coronavirus
virus-like particles with Glaxo's pandemic adjuvant system.
Coronavirus virus-like particles mimic the structure of the virus
responsible for Covid-19, allowing them to be recognized by the
immune system.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
July 07, 2020 08:55 ET (12:55 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
